Drug news
Novartis cancels development of Valdoxan in the USA
Novartis has cancelled development of agomelatine (AGO178) in major depressive disorder in the USA. The drug is known as Valdoxan in the rest of the world where it originated with and is marketed by Servier Laboratories which had ,in 2006, licensed the USA rights to Novartis.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.